SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-030466
Filing Date
2024-04-04
Accepted
2024-04-04 16:56:00
Documents
16
Period of Report
2024-04-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0203328-8k_aditxtinc.htm   iXBRL 8-K 68542
2 ARRANGEMENT AGREEMENT BETWEEN APPILI THERAPEUTICS, INC., ADITXT, INC. AND ADIVIR ea020332801ex2-1_aditxtinc.htm EX-2.1 739833
3 PRESS RELEASE, DATED APRIL 2, 2024 ea020332801ex99-1_aditxtinc.htm EX-99.1 29779
4 GRAPHIC ex99-1_001.jpg GRAPHIC 5498
  Complete submission text file 0001213900-24-030466.txt   1190761

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE adtx-20240401.xsd EX-101.SCH 3009
6 XBRL LABEL FILE adtx-20240401_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE adtx-20240401_pre.xml EX-101.PRE 22355
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0203328-8k_aditxtinc_htm.xml XML 3713
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

IRS No.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 24823769
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)